Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Background:
In order to survive, brain tumors must have a network of blood vessels to supply it with
oxygen and nutrients. The tumors produce substances that enable new blood vessels to form.
Tandutinib and Bevacizumab are experimental drugs that may prevent new blood vessel formation
and thereby slow or stop tumor growth in the brain.
Objectives:
To determine the safety and side effects of Tandutinib in combination with Bevacizumab in
patients with brain tumors.
To evaluate the response of brain tumors to treatment with Tandutinib and Bevacizumab.
Eligibility:
Patients 18 years of age and older with a malignant brain tumor for whom standard treatments
(surgery, radiation and chemotherapy) are no longer effective.
Design:
Patients receive treatment in 4-week cycles as follows: Tandutinib by mouth twice a day every
day and intravenous (through a vein) infusions of Bevacizumab over 90 minutes (or less if
well tolerated) every 2 weeks. Treatment may continue for up to 1 year, and possibly longer,
as long as there are no signs of tumor growth or serious treatment side effects.
Patients are evaluated with magnetic resonance imaging (MRI), computed tomography (CT) and
positron emission tomography (PET) scans before starting treatment and then periodically to
determine the response to treatment.
Patients have physical and neurological examinations every 4 weeks and blood tests every 2
weeks. They complete quality of life questionnaires every 4 weeks.